Skip to content
MarketScale
‹ Back to IndustriesSciences

Demands of Smartphone Camera Quality Drive Manufacturing Process Improvements

The article discusses the improvements in smartphone camera quality and how these demands are driving advancements in manufacturing processes. ZYGO, an optical technology company, is using its Compass microlens process metrology system to ensure that these manufacturing processes meet industry standards. This system helps in controlling the production of high-performance imaging camera modules in smartphones.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

Promoted content from SMART Technologies on MarketScale.

By Sciences · Promoted Content
Share
Demands of Smartphone Camera Quality Drive Manufacturing Process Improvements

Key takeaways

01

One billion smartphones are shipped each year, resulting in countless pictures taken.

02

Cell phone image quality has significantly improved in recent years.

03

ZYGO uses its Compass microlens process to maintain precision in smartphone camera manufacturing.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

With one billion smartphones shipped every year, there are an infinite number of pictures taken by these handheld devices as well. And in the past few years, cell phone image quality has undergone vast improvements. While the average consumer may not have noticed these enhancements, ZYGO has.

Not just because we’re an optical technology company who happen to make clever, innovative products. Rather, it’s because we get to see how our efforts impact the daily lives of millions of people as they capture life’s moments via their smart, but seemingly simple, phones.

Amazingly, these seemingly simple devices are packed with exceedingly smart technologies – one of which is the versatile camera lens module. Each smartphone’s camera lens module consists of multiple discrete lens elements that work in unison to provide high-performance imaging.

We are introducing our solution to the industry, and ultimately consumers – the Compass™ microlens process metrology system. The Compass system in an on-line production control tool that enables the rapid measurement and control of critical micro lenses and lens molds, ensuring that design parameters are being met while keeping the manufacturing process in control.

The Compass system employs proprietary and innovative ZYGO optical technology to uphold the precision, automation, and production throughput standards that can meet both current and future industry needs.

To ensure superior selfies, both now and beyond, check out the revolutionary ZYGO Compass™ micro lens process metrology system.

Read more at zygo.com

SMART Technologies

Part of this channel

SMART Technologies

Interactive learning technology trusted by educators worldwide

Visit the channel

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech is investing $750 million in a new fill-finish plant in Hillsboro. The facility will focus on the production of prefilled syringes and autoinjectors. The site is expected to become operational in 2031.

  • 01Genentech is investing $750 million in a new Hillsboro facility.
  • 02The facility will produce prefilled syringes and autoinjectors.
  • 03Operations at the plant are expected to begin in 2031.

Aug 27, 2026

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio's cell-free hpDNA will be used by Genezen as starting material for viral vectors, potentially reducing the need for AAV input DNA by 30%. This innovation may lead to changes in the specification of plasmids and project timelines in gene therapy programs.

  • 01Genezen will utilize 4basebio’s cell-free hpDNA for viral vector production.
  • 02This approach could reduce AAV input DNA requirements by 30%.
  • 03The adoption of hpDNA could lead to changes in plasmid specification and project timelines.

Aug 27, 2026

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers has terminated its agreement with Cellares, which raises concerns about the standardized capacity for cell therapy production. This decision highlights the importance of aligning manufacturing processes with production capabilities, rather than merely focusing on the availability of factory slots.

  • 01Bristol Myers has terminated its agreement with Cellares, affecting cell therapy capacity.
  • 02Aligning process fit with production capabilities is crucial for cell therapy success.
  • 03Factory slots alone are not sufficient to ensure supply plans in cell therapy production.

Aug 26, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512